<DOC>
	<DOCNO>NCT01290601</DOCNO>
	<brief_summary>This Phase II study design determine whether single 600 mg dose 400mg/day 3 day tafenoquine efficacious , well tolerate clear P. vivax malaria infection ( blood schizontocidal gametocytocidal activity ) prevent P. vivax relapse ( hypnozoite eradication ) . It also establish safety tolerability dose tafenoquine .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Tafenoquine Treatment Plasmodium Vivax Adults</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>1 . Positive smear P. vivax . 2 . Parasite density &gt; 500 &lt; 200,000/μl 3 . Age : 2060 year old 4 . Willing sign consent form 5 . Willing hospitalize 29 day remain malaria free region 60 day thereafter followup . 6 . A female eligible enter participate study : nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female postmenopausal , b childbearing potential , negative pregnancy ( urine serum ) test screen , agree comply recognize contraceptive method treatment stage study period 12 week stop study drug . Recognized contraceptive method include , abstinence , implant levonorgestrel , injectable progestogen , appropriate double barrier method use licensed contraceptive diaphragm condom ( partner ) intrauterine device condom . The use oral/patch contraceptive study consider sufficient contraceptive protection . 1 . Mixed malaria infection Field 's stain . 2 . Female subject pregnant , lactate unwilling/unable comply recognize contraceptive method treatment stage study period 12 week stop study drug . 3 . Symptoms severe vomit ( food inability take food previous 8 hour ) . 4 . Demonstrated glucose6phosphate dehydrogenase deficiency . 5 . Subject take antimalarial ( mefloquine , primaquine , chloroquine ) within past 30 day history 6 . Clinically significant illness ( intercurrent illness e.g . pneumonia , preexist condition e.g . renal disease , malignancy condition may affect absorption study medication e.g . severe diarrhea sign malnutrition define clinically ) . 7 . Clinically significant abnormal laboratory value determine history , physical examination routine blood chemistry hematology value ( laboratory guideline value exclusion hemoglobin &lt; 7 gm/dL , platelet &lt; 50,000/μl , White Blood Cell count ( WBC ) &lt; 2000/μl , serum creatinine &gt; 2.0mg/dL , ALT AST 3 time upper limit normal age . 8 . History allergy chloroquine , mefloquine , tafenoquine , primaquine 8aminoquinolines . 9 . Subject take another investigational drug within 30 day 5 half life ( whichever longer ) , study start . 10 . History previous eye surgery evidence corneal retinal abnormality identify baseline ophthalmological examination . 11 . Subjects take concomitant medication likely affect renal ophthalmic function know metabolize primarily cytochrome P450 isoforms 3A4/5 2C9 whose therapeutic effect occur within narrow plasma concentration range ( e.g . warfarin , ketoconazole ) . 12 . Subjects , examination study ophthalmologist , judge risk acute angle closure glaucoma . 13 . Females premenarchal .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>malaria</keyword>
	<keyword>Plasmodium vivax</keyword>
	<keyword>adult</keyword>
	<keyword>treatment</keyword>
	<keyword>tafenoquine</keyword>
</DOC>